Risk of non-alcoholic fatty liver disease for cardiovascular disease and all cause death in patients with type 2 diabetes mellitus

Researchers investigated the link between non-alcoholic fatty liver disease in individuals with type 2 diabetes mellitus (T2DM) and all-cause death and cardiovascular disease.

Apollo Therapeutics secures $226.5m to advance pipeline programmes

Apollo focuses on advancing major medical research into treatments. Credit: Gorodenkoff/Shutterstock.com. Portfolio biopharmaceutical company Apollo Therapeutics has secured $226.5m in a Series C funding round

September 7, 2023

Unified and concentrated lung cancer advocacy program results in 25% increase in research funding

A unified and concentrated lung cancer advocacy program in the United States resulted in a 25 percent increase in funding to a U.S.-based lung cancer

September 12, 2023

Neuronetics inks Greenbrook merger to acquire treatment centers

Dive Brief: Neuronetics said Monday it has agreed to merge with Greenbrook TMS to acquire treatment centers that use its mental health devices. Greenbrook provides

August 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.